相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats
Rana Samadfam et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Type 2 diabetes and bone fractures
Kendall F. Moseley
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2012)
Effect of Rosiglitazone on Bone Quality in a Rat Model of Insulin Resistance and Osteoporosis
Laura D. Sardone et al.
DIABETES (2011)
A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients
J. L. C. Borges et al.
DIABETES OBESITY & METABOLISM (2011)
Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee
A. Michael Parfitt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Guidelines for Assessment of Bone Microstructure in Rodents Using Micro-Computed Tomography
Mary L. Bouxsein et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis
John P. Bilezikian
AMERICAN JOURNAL OF MEDICINE (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Ian J. Douglas et al.
PLOS MEDICINE (2009)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial
Dorte Glintborg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
PPAR-γ regulates osteoclastogenesis in mice
Yihong Wan et al.
NATURE MEDICINE (2007)
Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells
S. Benvenuti et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2007)
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone
Oxana P. Lazarenko et al.
ENDOCRINOLOGY (2007)
The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
G. Viberti et al.
DIABETIC MEDICINE (2006)
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat
OP Lazarenko et al.
BONE (2006)
Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones
AM Schwab et al.
ENDOCRINOLOGY (2005)
The transcriptional basis of adipocyte development
ED Rosen
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2005)
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation
AA Ali et al.
ENDOCRINOLOGY (2005)
Bone is a target for the antidiabetic compound rosiglitazone
SO Rzonca et al.
ENDOCRINOLOGY (2004)
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
MA Sorocéanu et al.
JOURNAL OF ENDOCRINOLOGY (2004)
Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone)
V Sottile et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice
L Tornvig et al.
CALCIFIED TISSUE INTERNATIONAL (2001)
Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?
ME Nuttall et al.
BONE (2000)
Effects of peroxisome proliferator-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats
T Shibata et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Activation of peroxisome proliferator-activated receptor-γ pathway inhibits osteoclast differentiation
G Mbalaviele et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
